诺和诺德Novo Nordisk (NVO) 2015年年度报告「NYSE」.pdf

1、WHY DO SO MANY PEOPLE IN CITIES GET DIABETES?GLP-1 Small protein,big potential OBESITY How do you market a treatment for a disease that many doctors dont even acknowledge?GLOBAL DEMAND for diabetes products triggers major production investmentsCONTENTSThe Management review,as defined by the Danish F

2、inancial Statements Act(FSA),is found on pp 154 and 95.This Annual Report is published in English only.A shorter version,consisting of the Management review and excerpts from the consolidated statements,is available in Danish.In the event of any discrepancies,the English version shall prevail.01 Let

3、ter from the Chairman02 Letter from the CEO04 Novo Nordisk at a glance06 2015 performance and 2016 outlook14 Performance highlights16 Our strategy18 Novo Nordisk Way20 Pipeline overview22 193 million people do not know they have diabetes Are you one of them?24 Future diabetes medicines Whats next fr

4、om Novo Nordisks labs?26 GLP-1 Small protein,big potential28 Obesity care Building the market from scratch 30 Tackling the rise of diabetes in cities32 30 years of changing haemophilia33 The people behind it all34 The future of pharmaceuticals38 Global demand triggers major production investments40

5、Environmental strategy Doing more with less42 Managing risks44 Shares and capital structure46 Corporate governance49 Remuneration52 Board of Directors54 Executive Management55 Consolidated financial,social and environmental statements 105 Financial statements of the parent company 109 Managements st

6、atement and Auditors reports 112 Product overview 113 More information and referencesACCOMPLISHMENTS AND RESULTS 2015OUR BUSINESSFINANCIAL,SOCIAL AND ENVIRONMENTAL STATEMENTSGOVERNANCE,LEADERSHIP AND SHARESADDITIONAL INFORMATIONGLOBAL DEMANDtriggers major production investments38Tackling the rise of